Biocon Biologics announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics
License Application (BLA) for Bevacizumab filed by the company's partner Viatris (Mylan). The CRL informs the need for a satisfactory resolution of the observations made during the facility inspection conducted in August, 2022.
"We have submitted a comprehensive Corrective and Preventive Action (CAPA) plan, to the agency and are confident of addressing the observations within the stipulated timeframe. The CRL did not identify any outstanding scientific issues with the dossier", said the company spokesperson.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
